# Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy

> **NCT04779957** · PHASE2 · COMPLETED · sponsor: **University Hospital, Toulouse** · enrollment: 18 (actual)

## Conditions studied

- Kidney Transplantation
- Graft Failure

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT04779957
- **Lead sponsor:** University Hospital, Toulouse
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-01
- **Primary completion:** 2024-08-09
- **Final completion:** 2024-08-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04779957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04779957, "Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04779957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*